Burning Rock Biotech (BNR) and Dizal said Thursday that China's National Medical Products Administration has granted marketing approval for their jointly developed companion lung cancer diagnostic for the non-small cell lung cancer patients treatment sunvozertinib.
The approval of the companion diagnostic test is the result of the development of Burning Rock's LungCure diagnostic kit and Dizal's sunvozertinib.
The approval was based on the results of a study of sunvozertinib in platinum-based chemotherapy pretreated non-small cell lung cancer patients that met its primary endpoint in 61% of cases.
Price: 3.4500, Change: +0.17, Percent Change: +5.02
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。